Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia

Sleep

Volumn 36, Issue 12, 2013, Pages 1823-1830

  Ratti, Emiliangelo ^a   Carpenter, David J ^b   Zamuner, Stefano ^a   Fernandes, Sofia ^a   Squassante, Lisa ^a   Danker Hopfe, Heidi ^c   Archer, Graeme ^d   Robertson, Jonathan ^d   Alexander, Robert ^b   Trist, David G ^a   Merlo Pich, Emilio ^a  

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cognition; Insomnia; NK 1 receptor antagonist; Placebo; Polysomnography; Sleep; Substance P receptor; Vestipitant

Indexed keywords

NEUROKININ 1 RECEPTOR ANTAGONIST; PLACEBO; VESTIPITANT;

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EVENING DOSAGE; FATIGUE; FEMALE; HEADACHE; HUMAN; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; POLYSOMNOGRAPHY; PRIMARY INSOMNIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RHINOPHARYNGITIS; SLEEP; SLEEP TIME; TREATMENT DURATION; XEROSTOMIA;

COGNITION; INSOMNIA; NK-1 RECEPTOR ANTAGONIST; PLACEBO; POLYSOMNOGRAPHY; SLEEP; SUBSTANCE P RECEPTOR; VESTIPITANT;

ADULT; DOUBLE-BLIND METHOD; FEMALE; FLUOROBENZENES; HUMANS; MALE; MIDDLE AGED; NEUROKININ-1 RECEPTOR ANTAGONISTS; PIPERIDINES; POLYSOMNOGRAPHY; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84889002333     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.3208     Document Type: Article

References (46)

1. Buysse DJ. Insomnia. JAMA 2013;309:706-16.
2. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008;4:487-504.
3. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007;3(5 Suppl):S7-10.
4. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97-111.
5. Neubauer DN. The evolution and development of insomnia pharmacotherapies. J Clin Sleep Med 2007;3(5 Suppl):S11-5.
6. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000;162:225-33.
7. Nowell PD, Mazumdar S, Buysse DJ, Dew MW, Reynolds CF 3rd, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a metaanalysis of treatment efficacy. JAMA 1997;278:2170-7.
8. Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T; ZOLONG Study Group. Long-term efficacy and safety of zolpidem extendedrelease 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, doubleblind, placebo-controlled, parallel-group, multicenter study. Sleep 2008;31:79-90.
9. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, doubleblind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-9.
10. Roth T, Roehrs T. Determinants of residual effects of hypnotics. Accid Anal Prev 1985;17:291-6.
11. Petitjean S, Ladewig D, Meier CR, Amrein R, Wiesbeck GA. Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int Clin Psychopharmacol 2007;22:292-8.
12. Kan CC, Breteler MH, van der Ven AH, Timmermans MA, Zitman FG. Assessment of benzodiazepine dependence in alcohol and drug dependent outpatients: a research report. Subst Use Misuse 2001;36:1085-109.
13. Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. Eur J Pharmacol 2003;463:235-72.
14. Sakai K. Physiological properties and afferent connections of the locus coeruleus and adjacent tegmental neurons involved in the generation of paradoxical sleep in the cat. Prog Brain Res 1991;88:31-45.
15. Kohlmeier KA, Burns J, Reiner PB, Semba K. Substance P in the descending cholinergic projection to REM sleep-induction regions of the rat pontine reticular formation: anatomical and electrophysiological analyses. Eur J Neurosci 2002;15:176-96.
16. Ma QP, Bleasdale C. Modulation of brain stem monoamines and gammaaminobutyric acid by NK1 receptors in rats. Neuroreport 2002;13:1809-12.
17. Carter ME, Brill J, Bonnavion P, et al. Mechanism for Hypocretin-mediated sleep-to-wake transitions. Proc Natl Acad Sci U S A 2012;109:E2635-44.
18. Sakai, K. Sleep-waking discharge profiles of dorsal raphe nucleus neurons in mice. Neuroscience 2011;197:200-24.
19. Ebner K, Sartori SB, Singewald N. Tachykinin receptors as therapeutic targets in stress-related disorders. Curr Pharm Des 2009;15:1647-74.
20. Lieb K, Ahlvers K, Dancker K, et al. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology 2002;27:1041-9.
21. Ratti E, Bettica P, Alexander R, et al. Full central neurokin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. J Psychopharmacol 2013;27:424-34.
22. Kramer MS, Winokur A, Kelsey J, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004;29:385-92.
23. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998;281:1640-5.
24. Holsboer F. The role of peptides in treatment of psychiatric disorders. J Neural Transm Suppl 2003;17-34.
25. Ratti E, Bellew K, Bettica P, et al. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J Clin Psychopharmacol 2011;31:727-33.
26. Di Fabio R, Griffante C, Alvaro G, et al. Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl) piperazine-1-carboxylic acid [1-(R)-(3, 5-bis-trifluoromethylphenyl) ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist. J Med Chem 2009;52:3238-47.
27. Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL. Zolpidem and rebound insomnia-a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 1994;27:166-75.
28. Svetnik V, Ma J, Soper KA, et al. Evaluation of automated and semiautomated scoring of polysomnographic recordings from a clinical trial using zolpidem in the treatment of insomnia. Sleep 2007;30:1562-74.
29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, text revision (DSM-IV-TR). Washington DC, 2000.
30. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Washington DC: US Government Printing Office; 1968.
31. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001;2:297-307.
32. Lacritz LH, Cullum CM, Weiner MF, Rosenberg RN. Comparison of the hopkins verbal learning test-revised to the California verbal learning test in Alzheimer's disease. Appl Neuropsychol 2001;8:180-4.
33. Tyrer P, Murphy S, Riley P. The Benzodiazepine Withdrawal Symptom Questionnaire. J Affect Disord 1990;19:53-61.
34. Roth T. Measuring treatment efficacy in insomnia. J Clin Psychiatry 2004;65 Suppl 8:8-12.
35. Roth T, Drake C. Evolution of insomnia: current status and future direction. Sleep Med 2004;5 Suppl 1:S23-30.
36. Bélanger L, Vallières A, Ivers H, Moreau V, Lavigne G, Morin CM. Metaanalysis of sleep changes in control groups of insomnia treatment trials. J Sleep Res 2007;16:77-84.
37. Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ 2012;345:e8343.
38. McCall WV, D'Agostino R Jr, Dunn A. A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials. Sleep Med 2003;4:57-62.
39. De Gennaro L, Ferrara M. Sleep spindles: an overview. Sleep Med Rev 2003;7:423-40.
40. Destexhe A, Sejnowski TJ. Interactions between membrane conductances underlying thalamocortical slow-wave oscillations. Physiol Rev 2003;83:1401-53.
41. US Food and Drug Administration. Zolpidem containing products: drug safety communication - FDA requires lower recommended doses. 2013. Accessed February 2013. Available from: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm334738.htm.
42. Szabadi E. Drugs for sleep disorders: mechanisms and therapeutic prospects. Br J Clin Pharmacol 2006;61:761-6.
43. Challet E, Dugovic C, Turek FW, Van Reeth, O. The selective neurokinin 1 receptor antagonist R116301 modulates photic responses of the hamster circadian system. Neuropharmacology 2001;40:408-15.
44. Shibata S, Tsuneyoshi A, Hamada T, Tominaga K, Watanabe S. Effect of substance P on circadian rhythms of firing activity and the 2-deoxyglucose uptake in the rat suprachiasmatic nucleus in vitro. Brain Res 1992;597:257-63.
45. Reghunandanan V, Reghunandanan R. Neurotransmitters of the suprachiasmatic nuclei. J Circadian Rhythms 2006;4:2-22.
46. Kim DY, Kang HC, Shin HC, et al. Substance P plays a critical role in photic resetting of the circadian pacemaker in the rat hypothalamus. J Neurosci 2001;21:4026-31.